+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Global Human Combination Vaccines Market 2020-2024- Product Image
Global Human Combination Vaccines Market 2020-2024- Product Image

Global Human Combination Vaccines Market 2020-2024

  • ID: 5136985
  • Report
  • July 2020
  • Region: Global
  • 120 pages
  • TechNavio

FEATURED COMPANIES

  • Cadila Healthcare Ltd.
  • CSL Ltd.
  • Daiichi Sankyo Co. Ltd.
  • GlaxoSmithKline Plc
  • MassBiologics
  • Meiji Holdings Co. Ltd.
  • MORE
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Global Human Combination Vaccines Market 2020-2024

The human combination vaccines market is poised to grow by $ 4.98 bn during 2020-2024 progressing at a CAGR of 9% during the forecast period. The reports on human combination vaccines market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment. The market is driven by the increase in the pediatric population, increasing antiviral drug resistance and rise in cases of infectious diseases.

The human combination vaccines market analysis includes type segment and geographic landscape.

The human combination vaccines market is segmented as below:

By Type
  • Inactivated vaccine
  • Live attenuated vaccine
By Geographic Landscapes
  • North America
  • Europe
  • Asia
  • ROW
This study identifies the growing interest in R&D of new vaccines as one of the prime reasons driving the human combination vaccines market growth during the next few years. Also, the presence of government-sponsored programs and threats from bioterrorism will lead to sizable demand in the market.

The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters.

The human combination vaccines market covers the following areas:
  • Human combination vaccines market sizing
  • Human combination vaccines market forecast
  • Human combination vaccines market industry analysis
The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading human combination vaccines market vendors that include Cadila Healthcare Ltd., CSL Ltd., Daiichi Sankyo Co. Ltd., GlaxoSmithKline Plc, MassBiologics, Meiji Holdings Co. Ltd., Merck & Co. Inc., Mitsubishi Tanabe Pharma Corp., Sanofi, and Takeda Pharmaceutical Co. Ltd. Also, the human combination vaccines market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary.

This market research report provides a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast an accurate market growth.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Cadila Healthcare Ltd.
  • CSL Ltd.
  • Daiichi Sankyo Co. Ltd.
  • GlaxoSmithKline Plc
  • MassBiologics
  • Meiji Holdings Co. Ltd.
  • MORE
Executive Summary
  • Market Overview
Market Landscape
  • Threat of substitutes
  • Market ecosystem
  • Threat of rivalry
  • Value chain analysis
Market Sizing
  • Market condition
Market Segmentation by Type
  • Market definition
  • Market segments
  • Market segment analysis
  • Market size 2019
  • Comparison by Type
  • Inactivated vaccine - Market size and forecast 2019-2024
  • Market outlook: Forecast for 2019 - 2024
  • Live attenuated vaccine - Market size and forecast 2019-2024
Five Forces Analysis
  • Market opportunity by Type
  • Five force analysis
  • Bargaining power of buyers
Customer landscape

Geographic Landscape
  • Bargaining power of suppliers
  • Threat of new entrants
  • Geographic segmentation
  • Geographic comparison
  • Threat of substitutes
  • North America - Market size and forecast 2019-2024
  • Threat of rivalry
  • Europe - Market size and forecast 2019-2024
  • Market condition
  • Asia - Market size and forecast 2019-2024
Market Segmentation by Type
  • ROW - Market size and forecast 2019-2024
  • Market segments
  • Comparison by Type
  • Key leading countries
  • Market opportunity by geography
  • Inactivated vaccine - Market size and forecast 2019-2024
  • Live attenuated vaccine - Market size and forecast 2019-2024
  • Market drivers – Demand led growth
  • Market opportunity by Type
  • Market challenges
  • Market trends
Customer landscape

Geographic Landscape

Vendor Landscape
  • Vendor landscape
  • Geographic segmentation
  • Landscape disruption
  • Geographic comparison
Vendor Analysis
  • North America - Market size and forecast 2019-2024
  • Vendors covered
  • Europe - Market size and forecast 2019-2024
  • Asia - Market size and forecast 2019-2024
  • Market positioning of vendors
  • Cadila Healthcare Ltd.
  • ROW - Market size and forecast 2019-2024
  • CSL Ltd.
  • Key leading countries
  • Daiichi Sankyo Co. Ltd.
  • Market opportunity by geography
  • GlaxoSmithKline Plc
  • Market drivers – Demand led growth
  • MassBiologics
  • Market challenges
  • Meiji Holdings Co. Ltd.
  • Market trends
Vendor Landscape
  • Merck & Co. Inc.
  • Vendor landscape
  • Mitsubishi Tanabe Pharma Corp.
  • Landscape disruption
  • Sanofi
Vendor Analysis
  • Vendors covered
  • Market positioning of vendors
  • Scope of the report
  • Currency conversion rates for US$
  • Cadila Healthcare Ltd.
  • Research methodology
  • CSL Ltd.
  • List of abbreviations
  • Daiichi Sankyo Co. Ltd.
  • GlaxoSmithKline Plc
  • MassBiologics
  • Meiji Holdings Co. Ltd.
  • Merck & Co. Inc.
  • Mitsubishi Tanabe Pharma Corp.
  • Sanofi
  • Takeda Pharmaceutical Co. Ltd.
Appendix
  • Scope of the report
  • Currency conversion rates for US$
  • Research methodology
  • List of abbreviations
List of Exhibits
1: Key Finding 1
2: Key Finding 2
3: Key Finding 3
4: Key Finding 5
5: Key Finding 6
6: Key Finding 7
7: Key Finding 8
8: Parent market
9: Market characteristics
10: Offerings of vendors included in the market definition
11: Market segments
12: Global - Market size and forecast 2019 - 2024 ($ million)
13: Global market: Year-over-year growth 2019 - 2024 (%)
14: Five forces analysis 2019 & 2024
15: Bargaining power of buyers
16: Bargaining power of suppliers
17: Threat of new entrants
18: Threat of substitutes
19: Threat of rivalry
20: Market condition - Five forces 2019
21: Type - Market share 2019-2024 (%)
22: Comparison by Type
23: Inactivated vaccine - Market size and forecast 2019-2024 ($ million)
24: Inactivated vaccine - Year-over-year growth 2019-2024 (%)
25: Live attenuated vaccine - Market size and forecast 2019-2024 ($ million)
26: Live attenuated vaccine - Year-over-year growth 2019-2024 (%)
27: Market opportunity by Type
28: Customer landscape
29: Market share by geography 2019-2024 (%)
30: Geographic comparison
31: North America - Market size and forecast 2019-2024 ($ million)
32: North America - Year-over-year growth 2019-2024 (%)
33: Europe - Market size and forecast 2019-2024 ($ million)
34: Europe - Year-over-year growth 2019-2024 (%)
35: Asia - Market size and forecast 2019-2024 ($ million)
36: Asia - Year-over-year growth 2019-2024 (%)
37: ROW - Market size and forecast 2019-2024 ($ million)
38: ROW - Year-over-year growth 2019-2024 (%)
39: Key leading countries
40: Market opportunity by geography ($ million)
41: Impact of drivers and challenges
42: Vendor landscape
43: Landscape disruption
44: Industry risks
45: Vendors covered
46: Market positioning of vendors
47: Cadila Healthcare Ltd. - Overview
48: Cadila Healthcare Ltd. - Business segments
49: Cadila Healthcare Ltd. - Key offerings
50: Cadila Healthcare Ltd. - Key customers
51: Cadila Healthcare Ltd. - Segment focus
52: CSL Ltd. - Overview
53: CSL Ltd. - Business segments
54: CSL Ltd. - Key offerings
55: CSL Ltd. - Key customers
56: CSL Ltd. - Segment focus
57: Daiichi Sankyo Co. Ltd. - Overview
58: Daiichi Sankyo Co. Ltd. - Business segments
59: Daiichi Sankyo Co. Ltd. - Key offerings
60: Daiichi Sankyo Co. Ltd. - Key customers
61: Daiichi Sankyo Co. Ltd. - Segment focus
62: GlaxoSmithKline Plc - Overview
63: GlaxoSmithKline Plc - Business segments
64: GlaxoSmithKline Plc - Key offerings
65: GlaxoSmithKline Plc - Key customers
66: GlaxoSmithKline Plc - Segment focus
67: MassBiologics - Overview
68: MassBiologics - Product and service
69: MassBiologics - Key offerings
70: MassBiologics - Key customers
71: MassBiologics - Segment focus
72: Meiji Holdings Co. Ltd. - Overview
73: Meiji Holdings Co. Ltd. - Business segments
74: Meiji Holdings Co. Ltd. - Key offerings
75: Meiji Holdings Co. Ltd. - Key customers
76: Meiji Holdings Co. Ltd. - Segment focus
77: Merck & Co. Inc. - Overview
78: Merck & Co. Inc. - Business segments
79: Merck & Co. Inc. - Key offerings
80: Merck & Co. Inc. - Key customers
81: Merck & Co. Inc. - Segment focus
82: Mitsubishi Tanabe Pharma Corp. - Overview
83: Mitsubishi Tanabe Pharma Corp. - Business segments
84: Mitsubishi Tanabe Pharma Corp. - Key offerings
85: Mitsubishi Tanabe Pharma Corp. - Key customers
86: Mitsubishi Tanabe Pharma Corp. - Segment focus
87: Sanofi - Overview
88: Sanofi - Business segments
89: Sanofi - Key offerings
90: Sanofi - Key customers
91: Sanofi - Segment focus
92: Takeda Pharmaceutical Co. Ltd. - Overview
93: Takeda Pharmaceutical Co. Ltd. - Product and service
94: Takeda Pharmaceutical Co. Ltd. - Key offerings
95: Takeda Pharmaceutical Co. Ltd. - Key customers
96: Takeda Pharmaceutical Co. Ltd. - Segment focus
97: Currency conversion rates for US$
98: Research Methodology
99: Validation techniques employed for market sizing
100: Information sources
101: List of abbreviations
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Cadila Healthcare Ltd.
  • CSL Ltd.
  • Daiichi Sankyo Co. Ltd.
  • GlaxoSmithKline Plc
  • MassBiologics
  • Meiji Holdings Co. Ltd.
  • MORE
The publisher recognizes the following companies as the key players in the global human combination vaccines market: Cadila Healthcare Ltd., CSL Ltd., Daiichi Sankyo Co. Ltd., GlaxoSmithKline Plc, MassBiologics, Meiji Holdings Co. Ltd., Merck & Co. Inc., Mitsubishi Tanabe Pharma Corp., Sanofi, and Takeda Pharmaceutical Co. Ltd..

Commenting on the report, an analyst from the research team said: "The latest trend gaining momentum in the market is growing interest in R&D of new vaccines."

According to the report, one of the major drivers for this market is the increase in the pediatric population.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
  • Cadila Healthcare Ltd.
  • CSL Ltd.
  • Daiichi Sankyo Co. Ltd.
  • GlaxoSmithKline Plc
  • MassBiologics
  • Meiji Holdings Co. Ltd.
  • Merck & Co. Inc.
  • Mitsubishi Tanabe Pharma Corp.
  • Sanofi
  • Takeda Pharmaceutical Co. Ltd.
Note: Product cover images may vary from those shown

Loading
LOADING...

Adroll
adroll